Skip to main content

GenMark Diagnostics, Inc. (GNMK)

Apr 22, 2021 - GNMK was delisted (reason: acquired by Roche)
24.10
+0.06 (0.25%)
After-hours:
24.04
0.00 (0.00%)
At close:
Market Cap1.77B
Revenue (ttm)171.55M
Net Income (ttm)-18.64M
Shares Out71.81M
EPS (ttm)-0.28
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume-
Open-
Previous Close24.04
Day's Range24.03 - 24.06
52-Week Range8.47 - 24.25
Beta3.07
AnalystsBuy
Price Target22.52 (-6.3%)
Est. Earnings DateMay 4, 2021

About GNMK

GenMark Diagnostics, Inc., a molecular diagnostics company, engages in the developing and commercializing molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company also offers Blood Culture Identification Gram-Positive and Negative pa...

IndustryHealth Care Equipment & Supplies
IPO DateMay 28, 2010
Employees618
Stock ExchangeNASDAQ
Ticker SymbolGNMK
Full Company Profile

Financial Performance

In 2020, GNMK's revenue was $171.55 million, an increase of 94.90% compared to the previous year's $88.02 million. Losses were -$18.64 million, -60.63% less than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for GNMK stock is "Buy." The 12-month stock price forecast is 22.52, which is a decrease of -6.32% from the latest price.

Price Target
$22.52
(-6.32% downside)
Analyst Consensus: Buy

News

GenomeWeb Index Drops 3% for 2nd Consecutive Month

Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% inc...

Other symbols:ADPTBRNVIVO
6 months ago - GuruFocus

INVESTIGATION ALERT: Halper Sadeh LLP Investigates LMNX, NUAN, CADE, GNMK; Shareholders are Encouraged to Contact the...

NEW YORK, April 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX)  concerning potent...

Other symbols:CADELMNXNUAN
6 months ago - PRNewsWire

Italian Diagnostic Developer Calls Luminex a 'Perfect Fit'

Investors reacted favorably over the announcement that Saluggia, Italy-based DiaSorin SpA (MIL:DIA) is paying $1.8 billion to purchase Austin, Texas-based Luminex Corp. (NASDAQ:LMNX), a developer of pro...

Other symbols:LMNXQDEL
6 months ago - GuruFocus

GenMark Diagnostics (GNMK) Enters Overbought Territory

GenMark Diagnostics (GNMK) has moved higher as of late, but there could definitely be trouble on the horizon for this company

6 months ago - Zacks Investment Research

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of GenMark Diagnostics, Inc. - GNMK

NEW YORK, March 19, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class ...

6 months ago - PRNewsWire

GENMARK DIAGNOSTICS INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating the GenMark Diagn...

NEW YORK and SAN DIEGO, March 16, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating GenMark Diagnostics ("GenMark") (NASDAQ: GNMK) regarding possible brea...

6 months ago - PRNewsWire

GenMark Diagnostics (GNMK) Soars 29.6%: Is Further Upside Left in the Stock?

GenMark Diagnostics (GNMK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price in...

7 months ago - Zacks Investment Research

Why GenMark Stock Soared Today

A healthcare titan is acquiring the diagnostic-test maker for a hefty premium.

7 months ago - The Motley Fool

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of GenMark Diagnostics, Inc. Buyout

WILMINGTON, Del., March 15, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating GenMark Diagnostics, Inc. (“GenMark”) (NASDAQ GM: GNMK) regarding possible breaches of fiducia...

7 months ago - GlobeNewsWire

GNMK Grabs Fresh Highs on Billion-Dollar Buyout Buzz

GenMark Diagnostics Inc (NASDAQ:GNMK) stock is surging today, up 29.1% to trade at $23.88 at last check, after news of its buyout.

7 months ago - Schaeffers Research

SHAREHOLDER ALERT: WeissLaw LLP Investigates GenMark Diagnostics, Inc.

NEW YORK, March 15, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GenMark Diagnostics, Inc. ("GenMark" o...

7 months ago - PRNewsWire

GENMARK DIAGNOSTICS INVESTIGATION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP is investigating the GenMark Diagn...

NEW YORK and SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating GenMark Diagnostics (“GenMark”) (NASDAQ: GNMK) regarding possible ...

7 months ago - GlobeNewsWire

GenMark Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of GenMark Diagnostics, ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of GenMark Diagnostics, Inc. (NASDAQ: GNMK) to Roche is fair to GenMark shareholders. Un...

7 months ago - Business Wire

Roche (RHHBY) Inks Deal to Acquire GenMark Diagnostics for $1.8B

Roche (RHHBY) signs an agreement to acquire GenMark Diagnostics to test a broad range of pathogens using one patient sample. The deal is valued at around $1.8 billion on a fully diluted basis.

7 months ago - Zacks Investment Research

Roche to buy U.S. based GenMark Diagnostics for £1.29 billion

Roche Holding AG (SWX: RO) said on Monday that it will buy GenMark Diagnostics (NASDAQ: GNMK) for £1.29 billion. The all-cash deal translates to £17.25 per share.

7 months ago - Invezz

Roche Diagnostics CEO: GenMark deal will further expand global reach

Roche Diagnostics CEO Thomas Schinecker discusses the Swiss pharma company's acquisition of GenMark Diagnostics for $1.8 billion.

7 months ago - CNBC International TV

Roche Boosts Diagnostics Portfolio With $1.8B Bet On COVID-19 Test Manufacturer GenMark

Swiss drug giant Roche Holding AG (OTC: RHHBY) announced a big-ticket acquisition that would boost its presence in the diagnostics market, setting the tempo for a merger Monday. What Happened: Roche sai...

7 months ago - Benzinga

Roche agrees to buy GenMark Diagnostics in $1.8 billion deal

Roche will buy GenMark Diagnostics, a U.S.-based maker of molecular diagnostic tests in a $1.8 billion deal, the Swiss pharmaceuticals manufacturer said on Monday.

7 months ago - Reuters

GenMark ePlex® RP2 Panel Predicted to Detect Known SARS-CoV-2 Variants Currently in Circulation Based on in silico An...

CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its eP...

7 months ago - GlobeNewsWire

GenMark Diagnostics (GNMK) Expected to Beat Earnings Estimates: Should You Buy?

GenMark Diagnostics (GNMK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems...

7 months ago - GlobeNewsWire

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels

Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients Major teaching hospital in Grenoble, France demonstrates t...

7 months ago - GlobeNewsWire

GenMark Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021

CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close...

8 months ago - GlobeNewsWire

GenMark Surges On Report Of Potential Takeover Amid Interest From Buyers: Bloomberg

Bloomberg stated that GenMark Diagnostics Inc (NASDAQ: GNMK) is reportedly exploring a sale and has been contacted by multiple potential buyers. The company is said to have engaged a financial advisor t...

8 months ago - Benzinga

Why GenMark Diagnostics Stock Is Soaring Today

The company could be a potential acquisition target.

8 months ago - The Motley Fool